Examination of the antiproliferative activity of iron chelators: Multiple cellular targets and the different mechanism of action of triapine compared with desferrioxamine and the potent pyridoxal isonicotinoyl hydrazone analogue 311

Clinical Cancer Research

Volumn 9, Issue 1 I, 2003, Pages 402-414

  Chaston, Timothy B ^a   Lovejoy, David B ^a   Watts, Ralph N ^a   Richardson, Des R ^a,b  

^a HEART RESEARCH INSTITUTE   (Australia)

^b CHILDREN S CANCER INSTITUTE AUSTRALIA FOR MEDICAL RESEARCH   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

3 AMINOPICOLINALDEHYDE THIOSEMICARBAZONE; ASCORBIC ACID; BENZOIC ACID; CHELATING AGENT; DEFEROXAMINE; FREE RADICAL; IRON; IRON CHELATOR 311; PLASMID DNA; REGULATOR PROTEIN; UNCLASSIFIED DRUG;

ARTICLE; CANCER CELL CULTURE; CELL CYCLE; CELL PROLIFERATION; CONTROLLED STUDY; CYTOTOXICITY; DNA DEGRADATION; DRUG ACTIVITY; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG STRUCTURE; ENDOTHELIUM CELL; FIBROBLAST; HEMATOPOIETIC STEM CELL; HUMAN; HUMAN CELL; HYDROXYLATION; IRON CHELATION; IRON METABOLISM; IRON TRANSPORT; MACROPHAGE; MONOCYTE; MUSCLE CELL; NEUROBLASTOMA; NEUROEPITHELIOMA; OXIDATION REDUCTION REACTION; PRECIPITATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; RNA BINDING; SKELETAL MUSCLE; TARGET CELL; UMBILICAL VEIN;

ANIMALS; ASCORBIC ACID; BLOTTING, NORTHERN; BLOTTING, WESTERN; CELL DIVISION; CHELATING AGENTS; DEFEROXAMINE; DNA; DOSE-RESPONSE RELATIONSHIP, DRUG; ELECTRON SPIN RESONANCE SPECTROSCOPY; FREE RADICALS; GLUTATHIONE; HUMANS; IRON; IRON CHELATING AGENTS; ISONIAZID; MODELS, CHEMICAL; OXIDATION-REDUCTION; OXYGEN; PLASMIDS; PROTEIN BINDING; PYRIDINES; RATS; THIOSEMICARBAZONES; TIME FACTORS; TUMOR CELLS, CULTURED;

EID: 0037237032     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (69)

1. Hoffbrand, A. V., Ganeshaguru, K., Hooton, J. W. L., and Tatersall, M. H. N. Effect of iron deficiency and desferrioxamine on DNA synthesis in human cells. Br. J. Haematol., 33: 517-526, 1976.
2. Bergeron, R. J., Cavanaugh, P. F. Jr., Kline, S. J., Hughes, R. G. Jr., Elliot, G. T., and Porter, C. W. Antineoplastic and antiherpetic activity of spermidine catecholamide iron chelators. Biochem. Biophys. Res. Commun., 121: 848-854, 1984.
3. Hoyes, K. P., Hider, R. C., and Porter, J. B. Cell cycle synchronization and growth inhibition by 3-hydroxypyridin-4-one iron chelators in leukemic cell lines. Cancer Res., 52: 4591-4599, 1992.
4. Seligman, P., Schleicher, R. B., Siriwardana, G., Domenico, J., and Gelfand, E. W. Effects of agents that inhibit cellular iron incorporation on bladder cell proliferation. Blood, 82: 1608-1617, 1993.
5. Torti, S. V., Torti, F. M., Whitman, S. P., Brechbiel, M. W., Park, G., and Planalp, R. P. Tumor cell cytotoxicity of a novel metal chelator. Blood, 92: 1384-1389, 1998.
6. Richardson, D. R. Iron chelators as effective anti-proliferative agents. Can. J. Physiol. Pharmacol., 75: 1164-1180, 1997.
7. Larrick, J. W., and Cresswell, P. Modulation of cell surface iron transferrin receptors by cellular density and the state of activation. J. Supramol. Struct., 11: 579-586, 1979.
8. Richardson, D. R., and Baker, E. Two mechanisms of iron uptake from transferrin by melanoma cells. The effect of desferrioxamine and ferric ammonium citrate. J. Biol. Chem., 267: 13972-13979, 1992.
9. Richardson, D. R., and Baker, E. The uptake of iron and transferrin by the human melanoma cell. Biochim. Biophys. Acta, 1053: 1-12, 1990.
10. Kemp, J. D., Thorson, J. A., Stewart, B. C., and Naumann, P. W. Inhibition of hematopoietic tumor growth by combined treatment with deferoxamine and an IgG monoclonal antibody against the Transferrin receptor: evidence for a threshold model of iron deprivation toxicity. Cancer Res., 52: 4144-4148, 1992.
11. Kemp, J. D., Cardillo, T., Stewart, B. C., Kehrberg, E., Weiner, G., Hedland, B., and Naumann, P. W. Inhibition of lymphoma growth in vivo by combined treatment with hydroxyethyl starch deferoxamine conjugate and IgG monoclonal antibodies against the Transferrin receptor. Cancer Res., 55: 3817-3824, 1995.
12. Chan, S. M., Hoffer, P. B., Maric, N., and Duray, P. Inhibition of gallium-67 uptake in melanoma by an anti-human Transferrin receptor monoclonal antibody. J. Nucl. Med., 28: 1303-1307, 1987.
13. Chitamber, C. R., and Seligman, P. A. Effects of different Transferrin forms on Transferrin receptor expression, iron uptake, and cellular proliferation of human leukemic HL60 cells: mechanisms responsible for the specific cytotoxicity of Transferrin-gallium. J. Clin. Investig., 78: 1538-1546, 1986.
14. Blatt, J., and Stitely, S. Antineuroblastoma activity of desferrioxamine in human cell lines. Cancer Res., 47: 1749-1750, 1987.
15. Estrov, Z., Tawa, A., Wang, X-H., Dube, I. D., Sulh, H., Cohen, A., Gelfand, E. W., and Freedman, M. H. In vivo and in vitro effects of desferrioxamine in neonatal acute leukemia. Blood, 69: 757-761, 1987.
16. Becton, D. L., and Bryles, P. Deferoxamine inhibition of human neuroblastoma viability and proliferation. Cancer Res., 48: 7189-7192, 1988.
17. Donfrancesco, A., Deb, G., Dominici, C., Pileggi, D., Castello, M. A., and Helson, L. Effects of a single course of deferoxamine in neuroblastoma patients. Cancer Res., 50: 4929-4930, 1990.
18. Donfrancesco, A., Deb, G., Dominici, C., Angioni, A., Caniglia, M., De Sio, L., Fidani, P., Amici, A., and Helson, L. Deferoxamine, cyclophosphamide, etoposide, carboplatin, and thiotepa (D-CECat): A new cytoreductive chelation-chemotherapy regimen in patients with advanced neuroblastoma. Am. J. Clin. Oncol., 15: 319-322, 1992.
19. Donfrancesco, A., De Bernardi, B., Carli, M., Mancini, A., Nigro, M., De Sio, L., Casale, F., Bagnulo, S., Helson, L., and Deb, G. Deferoxamine (D) followed by cytoxan (C), etoposide (E), carboplatin (Ca), thio-TEPA (T), induction regimen in advanced neuroblastoma. Eur. J. Cancer, 31A: 612-615, 1995.
20. Dezza, L., Cazzola, M., Danova, M., Carlo-Stella, C., Bergamaschi, G., Brugnatelli, S., Invernizzi, R., Mazzini, G., Riccardi, A., and Ascari, E. Effects of desferrioxamine on normal and leukemic human hematopoietic cell growth: in vitro and in vivo studies. Leukemia (Baltimore), 3: 104-107, 1989.
21. Thelander, L., and Reichard, P. The reduction of ribonucleotides. Annu. Rev. Biochem., 48: 133-158, 1979.
22. Cooper, C. E., Lynagh, G. R., Hoyes, K. P., Hider, R. C., Cammack, R., and Porter, J. B. The relationship of intracellular iron chelation to the inhibition and regeneration of human ribonucleotide reductase. J. Biol. Chem., 271: 20291-20299, 1996.
23. Elford, H. L., Freese, M., Passamani, E., and Morris, H. P. Ribonucleotide reductase and cell proliferation. J. Biol. Chem., 245: 5228-5233, 1970.
24. Weber, G. Enzymology of cancer cells. N. Engl. J. Med., 296: 486-493, 1977.
25. Takeda, E., and Weber, G. Role of ribonucleotide reductase in expression in the neoplastic program. Life Sci., 28: 1007-1014, 1981.
26. Witt, L., Yap, T., and Blakely, R. L. Regulation of ribonucleotide reductase activity and its possible exploitation in chemotherapy. Adv. Enzyme Regul., 17: 157-171, 1979.
27. Agrawal, K. C., and Sartorelli, A. C. The chemistry and biological activity of α-(N)-heterocyclic carboxaldehyde thiosemicarbazones. Prog. Med. Chem., 15: 321-356, 1978.
28. Finch, R. A., Liu, M-C., Grill, S. P., Rose, W. C., Loomis, R., Vasquez, K. M., Cheng, Y-C., and Sartorelli, A. C. Triapine (3-amino-pyridine-2-carboxaldehyde-thiosemicarbazone): a potent inhibitor of ribonucleotide reductase activity with broad spectrum antitumor activity. Biochem. Pharmacol., 59: 983-991, 2000.
29. French, F. A., and Blanz, E. J., Jr. The carcinostatic activity of α-(N)-heterocyclic carboxaldehyde thiosemicarbazones. I. Isoquinoline-1-carboxaldehyde thiosemicarbazone. Cancer Res., 25: 1454-1458, 1965.
30. Levinson, W, E. Chelating substances. Antibiotics Chemother., 27: 288-306, 1980.
31. Creasey, W. A., Agrawal, K. C., Capizzi, R. L., Stinson, K. K., and Sartorelli, A. C. Studies of the anti-neoplastic activity and metabolism of α-(N)-heterocyclic carboxaldehyde thiosemicarbazones in dogs and mice. Cancer Res., 32: 565-572, 1972.
32. DeConti, R. C., Toftness, B. R., Agrawal, K. C., Tomchick, R., Mead, J. A. R., Bertino, J. R., Sartorelli, A. C., and Creasey, W. A. Clinical and pharmacological studies with 5-hydroxy-2-formylpyridine thiosemicarbazone. Cancer Res., 32: 1455-1462, 1972.
33. Krakoff, I. H., Etcubanas, E., Tan, C., Mayer, K., Bethune, V., and Burchenai, J. H. Clinical trial of 5-hydroxypicolinaldehyde thiosemicarbazone (5-HP: NSC-107392), with special reference to its Fe chelating properties. Cancer Chemother. Rep., 53: 207-212, 1974.
34. Liu, M. C., Lin, T. S., and Sartorelli, A. C. Synthesis and antitumor evaluation of amino derivatives of pyridine-2-carboxaldehyde thiosemicarbazone. J. Med. Chem., 35: 3672-3677, 1992.
35. Cory, J. G., Cory, A. H., Rappa, G., Lorico, A., Liu, M. C., Lin, T. S., and Sartorelli, A. C. Inhibitors of ribonucleotide reductase. Comparative effects of amino- and hydroxy-substituted pyridine-2-carbox-aldehyde thiosemicarbazones. Biochem. Pharmacol., 48: 335-344, 1994.
36. Richardson, D. R., Tran, E., and Ponka, P. The potential of iron chelators of the pyridoxal isonicotinoyl hydrazone class as effective antiproliferative agents. Blood, 86: 4295-4306, 1995.
37. Richardson, D. R., and Milnes, K. The potential of iron chelators of the pyridoxal isonicotinoyl hydrazone class as effective anti-proliferative agents II: The mechanism of action of ligands derived from salicylaldehyde benzoyl hydrazone and 2-hydroxy-1-naphthylaldehyde benzoyl hydrazone. Blood, 89: 3025-3038, 1997.
38. Darnell, G., and Richardson, D. R. The potential of analogues of the pyridoxal isonicotinoyl hydrazone class as effective anti-proliferative agents III: the effect of the ligands on molecular targets involved in proliferation. Blood, 94: 781-792, 1999.
39. Richardson, D. R., and Bernhardt, P. Crystal and molecular structure of 2-hydroxy-1-naphthylaldehyde isonicotinoyl hydrazone (NIH) and its iron(III) complex: an iron chelator with anti-proliferative activity. J. Biol. Inorg. Chem., 4: 266-273, 1999.
40. Richardson, D. R. Cytotoxic analogues of the iron(III) chelator pyridoxal isonicotinoyl hydrazone: Effect of complexation with copper(II), gallium(III), and iron(III) on their anti-proliferative activity. Antimicrob. Agents Chemother., 41: 2061-2063, 1997.
41. Gao, J., and Richardson, D. R. The potential of iron chelators of the pyridoxal isonicotinoyl hydrazone class as effective anti-proliferative agents IV. The mechanisms involved in inhibiting cell cycle progression. Blood. 98: 842-850, 2001.
42. McCrohon, J. A., Jessup, W., Handelsman, D. J., and Celermeyer, D, S. Androgen exposure increases human monocyte adhesion to vascular endothelium and expression of vascular cell adhesion molecule-1. Circulation, 99; 2317-2322, 1999.
43. Brown, A. J., Watts. G. F., Burnett, J. R., Dean, R. T., and Jessup, W. Sterol 27-hydroxylase acts on 7-ketocholestrol in human atherosclerotic lesions and macrophages in culture. J. Biol. Chem. 275; 27627-27633, 2000.
44. Eaves, C. J. Assays of hemopoietic progenitor cells. In: E. Beutler, M. A. Lichtman, B. S. Coller, and T. J. Kipps (eds.), Williams Hematology, Vol. 5. New York: McGraw Hill, 1995.
45. Leibold, E. A., and Munro, H. N. Cytoplasmic protein binds in vitro to a highly conserved sequence in the 5' untranslated region of ferritin heavy- and light-subunit mRNAs. Proc. Natl. Acad. Sci. USA. 85: 2171-2175, 1988.
46. Müllner, E. W., Neupert, B., and Kühn, L. C. A specific mRNA binding factor regulates the iron-dependent stability of the cytoplasmic Transferrin receptor mRNA. Cell, 58: 373-382, 1989.
47. Duling, D. R. Simulation of multiple isotropic spintrap EPR spectra. J. Magn. Reson., 104B: 105-110, 1994.
48. Dean, R. T., and Nicholson, P. The action of nine chelators on iron-dependent radical damage. Free Radic. Res., 20: 83-101, 1994.
49. Lovejoy, D. B., and Richardson, D. R. Novel "hybrid" iron chelators derived from aroylhydrazones and thiosemicarbazones demonstrate selective antiproliferative activity against tumor cells. Blood, 100: 666-676, 2002.
50. Hermes-Lima, M., Nagy, E., Ponka, P., and Schulman, H. M. The iron chelator pyridoxal isonicotinoyl hydrazone (PIH) protects plasmid pUC-18 DNA against. OH-mediated strand breaks. Free Radic. Biol. Med., 25: 875-880, 1998.
51. Sedlack, J., and Lindsay, R. Estimation of total, protein-bound, and nonprotein sulfhydryl groups in tissue with Ellman's reagent. Anal. Biochem., 25: 192-205, 1968.
52. Olson, R. D., MacDonald, J. S., van Boxtel, C. J., Boerth, R. C., Harbison, R. D., Slonim, A. E., Freeman, R. W., and Oates, J. A. Regulatory role of glutathione and soluble sulfhydryl groups in the toxicity of Adriamycin. J. Pharmacol. Exp. Ther., 215: 450-545, 1980.
53. Griffith, O. W., and Meister, A. Potent and specific inhibition of glutathione synthesis by buthionine sulfoximine (s-n-butyl homocysteine sulfoximine). J. Biol. Chem., 254: 7558-7560, 1979.
54. Watts, R. N., and Richardson, D. R. Nitrogen monoxide (NO) and glucose. Unexpected links between energy metabolism and NO-mediated iron mobilization from cells. J. Biol. Chem., 276: 4724-4732, 2001.
55. Olive, P. L. DNA precipitation assay: a rapid and simple method for detecting DNA damage in mammalian cells. Environ. Mol. Mutagen., 11: 487-495, 1988.
56. Kulp, K. S., Green, S. L., and Vulliet, R. Iron deprivation inhibits cyclin-dependent kinase activity and decreases cyclin D/CDK protein levels in asynchronous MDA-MB-453 human breast cancer cells. Exp. Cell Res., 229: 60-68, 1996.
57. Kwok, J., and Richardson, D. R. The cardioprotective effect of the iron chelator dexrazoxane (ICRF-187) on anthracycline-mediated cardiotoxicity. Redox Rep., 5: 317-324, 2000.
58. Gutteridge, J. M. C. Ferrous-salt-promoted damage to deoxyribose and benzoate. Biochem. J., 243: 709-714, 1987.
59. Singh, S., and Hider, R. C. Colorimetric detection of the hydroxyl radical: comparison of the hydroxyl-radical-generating ability of various iron complexes. Anal. Biochem., 171: 47-54, 1988.
60. Richardson, D. R., Hefter, G. T., May, P. M., Webb. J., and Baker, E. Iron chelators of the pyridoxal isonicotinoyl hydrazone class III. Formation constants with calcium(II), magnesium(II) and zinc(II). Biol. Metals, 2: 161-167, 1989.
61. Vitolo. L. M. W., Hefter, G. T., Clare, B. W., and Webb, J. Iron chelators of the pyridoxal isonicotinoyl hydrazone class. Part II. Formation constants with iron(III) and iron(II). Inorg. Chim. Acta, 170: 171-176, 1990.
62. Antholine, W., Knight, J., Whelan, H., and Petering, D. H. Studies of the reaction of 2-formylpyridine thiosemicarbazone and its iron and copper complexes with biological systems. Mol. Pharmacol., 13: 89-98, 1977.
63. Finch, R. A., Liu, M-C., Cory, A. H., Cory, J. G., and Sartorelli, A. C. Triapine (3-aminopyridine-2-carboxaldehyde thiosemicarbazone; 3-AP): An inhibitor of ribonucleotide reductase with antineoplastic activity. Adv. Enzyme Regul., 39: 3-12, 1999.
64. Sartorelli, A. C., Agrawal, K. C., Tsiftsoglou, A. S., and Moore. E. C. Characterization of the biochemical mechanism of action of α-(N)-heterocyclic carboxaldehyde thiosemicarbazones. Adv. Enzyme Regul., 15: 117-139, 1977.
65. Thelander, L., and Gräslund, A. Mechanism of inhibition of mammalian ribonucleotide reductase by the iron chelate of 1-formylisoquinoline thiosemicarbazone. J. Biol. Chem., 258: 4063-4066, 1983.
66. Salmon, S. E. Part VII. Chemotherapeutic agents-cancer chemotherapy. In: F. H. Meyers, E. Jawetz, E. Goldfien and A. Goldfien, (eds.), Review of Medical Pharmacology, pp. 477-513. Los Altos, CA: Lange Medical Publications, 1980.
67. Beckloff, G. L., Lemer, H. J., Frost, D., Russo-Alesi, F. M., and Gitomer, S. Hydroxyurea (NSC-32065) in biological fluids: dose-concentration relationship. Cancer Chemother. Rep., 48: 57-58. 1965.
68. Gwilt, P. R., and Tracewell, W. G. Pharmacokinetics and pharmacodynamics of hydroxyurea. Clin. Pharmacokinet., 34: 347-358, 1998.
69. Moore, E. C., and Hurlbert, R. B. The inhibition of ribonucleoside diphosphate reductase by hydroxyurea, guanazole and pyrazoloimidazole (IMPY). In: J. G. Cory and A. H. Cory (eds.), Inhibitors of Ribonucleoside Diphosphate Reductase Activity, pp. 165-201. Oxford: Pergamon Press, 1989.